1 citations,
October 2018 in “InTech eBooks” Only minoxidil and finasteride are FDA-approved for hair loss, with other treatments available but less effective or with side effects.
37 citations,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
14 citations,
February 2021 in “Journal of the European Academy of Dermatology and Venereology” A COVID-19 patient with severe hair loss did not improve with hair loss medication after stopping and restarting it due to the infection.
6 citations,
December 2013 in “Journal of Investigative Dermatology Symposium Proceedings” Alopecia areata involves complex immune and genetic factors, with potential treatment targets identified, but more research is needed.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
3 citations,
March 2021 in “Clinical, Cosmetic and Investigational Dermatology” Early treatment of Lupus Erythematosus Alopecia can prevent permanent hair loss, and various medications are effective.
January 2024 in “Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica/Revista de la Asociacion Colombiana de Dermatologia y Cirugia Dermatologica” Baricitinib successfully treated severe hair loss.
July 2023 in “Skin Research and Technology” Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
23 citations,
September 2017 in “Journal of the American Academy of Dermatology” Apremilast did not work for treating severe alopecia areata.
Alopecia Areata has no cure, treatments are limited, and the condition often recurs, but new therapies like JAK inhibitors show promise.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” The summit aimed to speed up finding treatments for alopecia areata.
25 citations,
April 2019 in “Journal of The American Academy of Dermatology” Using 2% tofacitinib cream with narrowband ultraviolet B improved facial vitiligo by 70% in patients who didn't respond to previous treatments, with no side effects reported.
September 2023 in “Dermatology and therapy” Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
July 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Assessing CD8+ T cell levels before surgery may improve vitiligo treatment outcomes.
271 citations,
May 2019 in “Cells” The secretome from mesenchymal stem cells is a promising treatment that may repair tissue and avoid side effects of stem cell transplantation.
23 citations,
April 2021 in “Journal of Clinical Medicine” Frontal Fibrosing Alopecia's cause is unclear, affects mainly postmenopausal women, and current treatments focus on stopping hair loss rather than regrowth.
18 citations,
January 2017 in “Journal der Deutschen Dermatologischen Gesellschaft” High and low doses of prednisolone helped 62% of children with severe alopecia regrow hair with some weight gain and mild acne as side effects.
5 citations,
November 2011 in “Expert Review of Dermatology” The document concludes that early diagnosis and a comprehensive treatment plan are crucial for managing hair loss in children, with a focus on both medical and psychological support.
March 2024 in “Clinical, cosmetic and investigational dermatology” Severe alopecia areata greatly impacts quality of life, mental health, and daily activities.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
March 2017 in “Fundamental & Clinical Pharmacology” The model and estimator can predict drug exposure in kidney transplant patients well.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
15 citations,
November 2020 in “Pharmaceutics” Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
October 2020 in “Revista médica sinergía/Revista médica sinergia” Alopecia areata is a complex condition causing hair loss, linked to genetics and immune system issues, and may be related to other autoimmune diseases; treatments vary in effectiveness.
June 2024 in “Indian Dermatology Online Journal” Topical tofacitinib is effective and safe for treating alopecia areata.
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
4 citations,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
January 2024 in “Wiadomości Lekarskie” Robotic hair transplantation with AI offers more reliable, precise, and efficient hair restoration.